CytomX is a biotechnology company focused on revolutionizing the monoclonal antibody field by creating a new generation of highly targeted antibody therapeutics.
CytomX's Probody™ Platform represents a transformational drug discovery and development approach for antibodies, enabling improved specificity, increased efficacy and decreased toxicity. This highly differentiated platform is based on a robust and growing intellectual property estate.
CytomX's novel platform is driving the development of Probodies, breakthrough antibody therapeutics that achieve unprecedented levels of diseased tissue-specific targeting. Probodies are designed to bind to antigens only in diseased tissue and not in healthy tissue, and therefore have the potential to open up new target space and expand the therapeutic index of current antibody therapies. The company's pipeline of Probody therapeutics is initially focusing on oncology, inflammation and other areas of high unmet medical need.
CytomX is dedicated to its mission of developing a pipeline of innovative biologic products to treat major unmet medical needs. To accomplish this, the CytomX team embraces its corporate values of integrity, commitment, creativity, teamwork, accountability and fun.
The Company was founded in Santa Barbara with technology licensed from University of California, Santa Barbara. CytomX moved to the San Francisco Bay Area in 2011, after raising its first round of venture capital. CytomX is led by an experienced and proven management team and financed by leading life science investors, including Third Rock Ventures, Canaan Partners and the Roche Venture Fund.